Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3 rectal cancer
2015-002773-38Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in rectal cancer, rectosigmoid cancer and colorectal cancer (CRC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Pathologic complete response rate. Started Aug 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
rectal cancerrectosigmoid cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2015-002773-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002773-38.